Objective: To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD).
such as tau (a measure of neuronal degeneration 8 ) and hyperphosphorylated tau (p-tau; a potential marker of tau pathology). 9 Several studies have examined the agreement between amyloid PET and CSF Ab42, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] but head-to-head studies comparing their diagnostic accuracy for incipient AD are scarce. Very few studies have used clinically relevant, consecutively recruited patients. To our knowledge, no previous study has compared the accuracy of regional amyloid PET and different CSF assays or ratios of CSF biomarkers such as Ab42/40, Ab42/total tau (t-tau), and Ab42/p-tau when identifying cases with incipient AD. We therefore performed a detailed head-to-head comparison of regional and global amyloid PET and CSF analysis with 2 different assays in a clinical cohort of consecutive patients with mild cognitive impairment who later developed AD dementia (MCI-AD). We also examined the diagnostic benefit of combining CSF and PET measures.
METHODS This study conducts a head-to-head comparison of the diagnostic accuracy of amyloid PET and CSF biomarkers for identifying early-stage AD. It provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.
Subjects. The present study population was part of the prospective and longitudinal Swedish BioFINDER study, which, among other cohorts, consecutively enrolls patients without dementia with mild cognitive symptoms (MCS) from 3 participating memory clinics in Sweden. More information about the design and populations is available at biofinder.se and in the online supplement (e-Methods on the Neurology ® Web site at Neurology.org). We included patients with MCS who had progressed to AD dementia during the follow-up period (hereafter referred to as MCI-AD). This resulted in a sample of 34 patients with MCI-AD. The mean follow-up time was 2.0 years (range 0. 8-3.4) . A consensus group (Katarina Nägga, P.J., S.P.) determined the follow-up diagnosis probable AD 23 in September 2014. The group was blinded to all biomarker data. At baseline in the MCS cohort, 3 patients (9%) had subjective cognitive decline and 31 (91%) had MCI (48% amnestic single-domain, 39% amnestic multidomain, and 12% nonamnestic). A total of 122 cognitively healthy elderly from the BioFINDER study were included as controls. 24 Standard protocol approvals, registrations, and patient consents. The Ethics Committee in Lund, Sweden, approved the study. All patients gave their written informed consent.
Amyloid PET scanning and analysis. Cerebral Ab deposition was visualized with the PET tracer 18 F-flutemetamol (approved by the Food and Drug Administration and the European Medical Agency). 25 PET/CT scanning of the brain was conducted at 2 sites using the same type of scanner (Gemini, Philips Healthcare, Best, the Netherlands). Baseline sum images from 90-110 minutes postinjection were analyzed using the software NeuroMarQ (GE Healthcare, Cleveland, OH). A volume of interest (VOI) template was applied for the following 9 bilateral regions: prefrontal, parietal, lateral temporal, medial temporal, sensorimotor, occipital, anterior cingulate, posterior cingulate/precuneus, and a global neocortical composite region. 26 The standardized uptake value ratio (SUVR) was defined as the uptake in a VOI normalized for the cerebellar cortex uptake.
CSF analysis. The procedure and analysis of the CSF followed the Alzheimer's Association Flow Chart for CSF biomarkers. 8 Baseline lumbar CSF samples were collected at the 3 centers and analyzed at one center on one occasion using single batch analysis according to a standardized protocol. 8 (table 1 and  reference 19 ). In sum, the PET tracer 18 F-florbetapir was used to quantify Ab in different brain regions (and globally), normalized for the cerebellar uptake. CSF Ab42, t-tau, and p-tau were measured using xMAP Luminex (Luminex Corp., Austin, TX) with the INNOBIA AlzBio3 kit (Innogenetics, Ghent, Belgium). 28 A consensus group blinded to the biomarker data determined the follow-up diagnoses.
Statistical analysis. Group differences were calculated with the Mann-Whitney U test (table 1). The area under the receiver operating characteristic (ROC) curve (AUC) was used to examine the diagnostic accuracy of the continuous CSF and PET variables (table 2). The 95% confidence interval (CI) and significance for differences between the AUCs were calculated using bootstrap techniques. 29 The AUCs of the combined CSF and PET variables were derived from logistic regressions. Nonoptimized and unbiased cutoffs were established using mixture modeling. 30 A Youden index (YI; sensitivity 1 specificity 2 1) was used for an easier comparison of sensitivities and specificities. Odds ratios (OR) were calculated with multivariate logistic regression analysis ( EI had a numerically poorer AUC compared to all PET variables except for the sensorimotor, occipital. and medial temporal regions, but the differences were not significant (p 5 0.09-0.40).
Combination of CSF and PET biomarkers. To examine the potential benefit of combining PET and CSF analysis, we tested models with CSF Ab42 IT /p-tau IT and the composite PET SUVR entered separately and together as predictors of diagnosis in logistic regression analyses. When used together, the AUC was 0.96 (95% CI 0.92-0.97) and both variables were independent significant predictors (p , 0.01). This was numerically higher than for models using the individual modalities, but the differences were not significant (AUC difference 0.021-0.047, p 5 0.07-0.08). A combined model of the composite PET SUVR and CSF p-tau IT The diagnostic accuracy of biomarkers used in the clinic should preferably not be very sensitive to smaller changes in cutoff values, if they are to be generalizable between different centers and settings. In figure 1, A Comparison with the ADNI data. Accuracies for CSF and PET biomarkers were also analyzed in the independent ADNI cohort (table 4). All CSF and PET variables had similar AUCs ranging from 0.86 to 0.87 and no significant differences were found (p 5 0.17-0.93). As in BioFINDER, CSF Ab42/t-tau and Ab42/p-tau had higher AUCs than CSF Ab42 alone (both 0.87 vs 0.85), but in ADNI the differences were not significant (p 5 0.60-0.65). In ADNI, the AUCs of t-tau (0.81, 95% CI 0.74-0.88) and p-tau (0.82, 95% CI 0.75-0.88) were lower than in Table 2 Classification of MCI-AD and healthy controls in BioFINDER based on ROC analyses in BioFINDER BioFINDER (t-tau 0.88, 95% CI 0.82-0.93 and p-tau 0.87, 95% CI 0.80-0.91; data not shown in the tables). However, no significant differences could be tested since the results were derived from 2 different cohorts. When combining CSF Ab42/p-tau and composite PET SUVR in ADNI, the AUC was 0.87 (95% CI 0.82-0.93). This did not differ significantly from using the variables separately (AUC difference: 0.00-0.01; p 5 0.40-0.53). DISCUSSION The main finding of this study was that the diagnostic accuracy of CSF and Ab PET biomarkers to identify MCI-AD was similar when using 18 F-flutemetamol amyloid PET and several different CSF biomarkers. Specifically, the best CSF measures (CSF Ab42/t-tau and Ab42/p-tau ratios) had similar diagnostic accuracies as the best PET measures (composite and cingulate SUVRs; table 2). We also found that no regional PET biomarker was better than the neocortical composite PET SUVR (table 2) . For CSF biomarkers, the CSF Ab42/t-tau or Ab42/p-tau ratios had significantly higher diagnostic accuracy compared to using CSF Ab biomarkers alone. When using unbiased cutoffs, CSF Ab42/t-tau had the highest sensitivity and specificity of all CSF and PET biomarkers (table 3) . Finally, the combination of the best CSF and PET biomarkers did not provide any added diagnostic value compared to using either modality separately. The overall results were replicated in an independent cohort (ADNI).
Although we found that CSF Ab42 IT and Ab42 EI / Ab40 EI performed similarly to the best SUVRs of 18 F-flutemetamol PET in terms of AUCs (table 2) , these CSF biomarkers generally had lower specificities than the PET biomarkers when using unbiased cutoffs (table 3) . The addition of t-tau or p-tau to Ab42 (as ratios) significantly increased the diagnostic accuracy of CSF biomarkers (table 2) . This supports the common usage of CSF Ab42 in combination with ttau or p-tau in clinical practice, and is in agreement with previous studies. [31] [32] [33] [34] The diagnostic accuracy of CSF Ab42 was lower for EUROIMMUN compared with INNOTEST (table 2 and figure e-3). This was partly overcome by using the Ab42/40 ratio, which did not improve the accuracy of Ab42 INNOTEST (table 2) . This finding has not been shown previously and needs to be replicated in future studies, since the causes are Table 3 ROC analysis in BioFINDER of MCI-AD and healthy controls based on unbiased cutoffs Area under the curve was calculated with ROC analysis. The 95% CI and significance for differences between the AUCs were calculated using bootstrap techniques with 5,000 bootstrap replicas. PET values are shown in standardized uptake value ratio and CSF levels in pg/mL (except for the CSF ratios). a Established with mixture modeling analysis (described in Methods). b Based on the ROC analysis (not derived from the logistic regression analysis). c Youden index (sensitivity 1 specificity 2 1) is provided for an easier comparison of the combined value of the sensitivity and specificity, e.g., the diagnostic accuracy of CSF and PET measures as dichotomized variables. The value is based on the unbiased cutoffs.
d A logistic regression analysis was performed with the diagnosis (MCI-AD or control) as the dependent variable and the dichotomized CSF/PET variable as a covariate to yield an OR. Age, sex, APOE e4 allele, memory function, and hippocampal volume were adjusted for in the model.
unknown. Few studies have compared different
ELISAs for CSF Ab42 to identify MCI-AD. Hertze et al. 33 found that CSF Ab42 analyzed with xMAP AlzBio3 had higher diagnostic accuracy compared with the Meso Scale Discovery (MSD) assay, but this was overcome by using the Ab42/Ab40 MSD ratio. , which have a slightly narrower span. The different cutoffs within this near optimal range thus only change the relationship between the sensitivity and specificity, but not the overall classification accuracy. This wide range of near optimal cutoffs suggests that the cutoffs are likely to produce high diagnostic accuracies in other populations. AUC 5 area under the receiver operating characteristic curve.
Similar to the present study, they showed that Ab42/ t-tau was superior to Ab42 and Ab42/Ab40.
A possible advantage of Ab PET over CSF Ab42 as an early marker for amyloid pathology is that Ab PET may be able to identify early region-specific pathology. However, this was not supported by our study, since the global Ab uptake performed similar compared to the best regional SUVRs (tables 2 and 4). Only one previous study has examined this and found similar results. 19 The similar AUCs for the best PET regions support the notion that the Ab deposition is uniformly distributed in the neocortical association areas already at the MCI stage of AD. 35 We used classification cutoffs established with mixture modeling, which is a robust way of determining unbiased thresholds and used in several studies. 20, 36, 37 Even so, the cutoffs (table 3) should not be considered generalizable, but study-specific for comparative purposes. However, figure 1 shows that although a cutoff is not optimized for the current population, it can still provide good diagnostic accuracy because of the broad range of high YI. The stability of cutoffs between populations is also supported by a previous cross-validation study on CSF Ab42 and amyloid PET cutoffs. 20 However, even though the classification accuracy stays the same, a change in cutoff will of course result in a higher sensitivity/lower specificity or lower sensitivity/higher specificity, and this must be taken into consideration depending on the clinical aim of the examination.
The overall results were similar between the Bio-FINDER and ADNI cohorts. In ADNI, the same comparable results between regional and composite SUVRs, as well as equal diagnostic accuracies of CSF and PET measures, were seen (table 4) . This similarity between studies is especially interesting considering the use of different PET tracers and different CSF assays. In both cohorts, numerically higher AUCs were seen for the CSF Ab42/t-tau or p-tau ratios compared with just Ab42, but in ADNI the increase was not significant (tables 2 and 4). This could be attributed to the poorer AUCs of t-tau and p-tau in ADNI (0.81 and 0.82; AlzBio3) compared with BioFINDER (0.88 and 0.87; EUROIMMUN and INNOTEST). A similar difference between INNOTEST and AlzBio3 regarding Ab42/tau ratios was also found in a previous study. 38 It was notable that the AUCs of all brain regions were similar in ADNI (AUC range 0.01; table 4), in contrast to BioFINDER (AUC range 0.17; table 2). The reason for this could be that in ADNI the regions were coarser and not able to detect differences between, e.g., the medial and lateral temporal lobe.
The diagnostic accuracy of Ab PET and CSF biomarkers to detect incipient AD has only been compared head-to-head in one previous study, which partly used the same ADNI data used for replication in the present study. 19 In that study, the accuracy between stable MCI (2-to 3-year follow-up without progression) and MCI-AD was compared. In the present study, we instead compared healthy elderly and patients with MCI-AD, which resulted in higher AUCs (on average about 0.05 in the ADNI study; compare reference 19 and table 4). The rationale behind comparing controls and MCI-AD is that .5-10 years of follow-up is required before one can say that a patient with MCI is truly stable. 36 Among patients with stable MCI with a short follow-up time, there are several cases with early-stage AD. These patients with stable MCI will in most cases be correctly identified as MCI-AD by the biomarkers, but result in Table 4 Classification of MCI-AD and healthy controls based on ROC analyses in ADNI false low specificity (and a false low AUC) due to the incorrect clinical diagnosis/short follow-up. We therefore compared patients with MCI-AD and controls, given the relatively short follow-up data in the ADNI and BioFINDER populations, for a more robust comparison of Ab biomarkers. The novelties of the present study compared with the previous study 19 include a comparison between MCI-AD and controls, a more detailed analysis of regional Ab PET data, analyses of ratios of CSF Ab42/Ab40, Ab42/t-tau, and Ab42/p-tau, a comparison of 2 different ELISAs for CSF Ab42, and evaluation of the combination of PET and CSF biomarkers.
The similar results we found for CSF biomarkers and amyloid PET suggest that other factors than their diagnostic accuracy may be considered when deciding which biomarker to use. CSF analysis has the advantages that it may easily incorporate other biomarkers to improve the differential diagnosis (e.g., leukocytes, albumin ratio, neurofilament, a-synuclein), requires less advanced instruments than PET, and is in some countries more available in clinical practice. Amyloid PET, on the other hand, is less invasive and has a higher reliability in longitudinal examinations and between centers. With appropriate standardized procedures, 20, 39, 40 CSF analysis and amyloid PET perform equally well and either method can be used in the clinical workup of AD for increased diagnostic accuracy. 
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